CXCL9 attenuated chemotherapy-induced intestinal mucositis by inhibiting proliferation and reducing apoptosis

详细信息    查看全文

• 作者：Xiaodong  ; Han¹ ; Zhenqian  ; Wu¹ ; Jianzhong  ; Di ; Ye  ; Pan ; Hongwei  ; Zhang ; Yibao  ; Du ; Zhe  ; Cheng ; Zhiming  ; Jin ; Zhigang  ; Wang ; Qi  ; Zheng  ; ;   ; ^{zhengqi1957@sina.cn} ; Pin  ; Zhang  ; ;   ; ^{zhangpin@sina.cn} ; Yu  ; Wang  ; ;   ; ^{wangyu11122@sina.cn}
• 关键词：CXCL9 ; Mucositis ; Proliferation ; Apoptosis
• 刊名：Biomedicine and Pharmacotherapy
• 出版年：2011
• 出版时间：December 2011
• 年：2011
• 卷：65
• 期：8
• 页码：547-554
• 全文大小：736 K

文摘

Mucositis arising from cancer chemotherapy is a common problem for which there is no definitive treatment. 5-fluorouracil (5-FU) is a common cytotoxic agent used to treat solid tumors. A global gene expression array was performed to identify genetic signals involved in the pathogenesis of mucositis. The chemokine (C-X-C motif) ligand?9 (CXCL9) was one of the candidates identified that presented a characteristic gene expression profile; its temporal expression pattern was correlated with the damage and regeneration phases of the small intestine upon 5-FU chemotherapy. We found that prophylactic CXCL9 administration was able to attenuate the severity of mucositis, weight loss and diarrhea caused by chemotherapy. CXCL9 also increased the tolerance of the mice to lethal-dose chemotherapy. Moreover, we demonstrated that CXCL9 was able to promote the proliferation and regeneration of intestinal cells by inhibiting the proliferation of normal intestinal mucosal cells prior to chemotherapy and by reducing the 5-FU-induced apoptosis in intestinal crypts. Thus, pretreatment with CXCL9 is a new and promising strategy for the alleviation of chemotherapy-induced intestinal mucositis in clinical settings.